Analysts' Views on MannKind's Fair Value Estimate and Future Prospects

Monday, Mar 23, 2026 4:31 pm ET1min read
MNKD--

MannKind's fair value estimate is US$7.50, with analysts clustering in the mid single digit to low double digit range. Recent commentary weighs Tyvaso DPI royalty risk against Afrezza, Furoscix, and the broader pipeline. Analysts have mixed views, with some seeing potential for the stock to reflect contributions from Furoscix and Afrezza, while others flag the challenge of disproving the bear case around potential franchise migration from Tyvaso DPI to a soft mist device.

Stay ahead of the market.

Get curated U.S. market news, insights and key dates delivered to your inbox.

Comments



Add a public comment...
No comments

No comments yet